Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 29.45 Million CNY | -68.42% |
| 2022 | 93.27 Million CNY | 93.62% |
| 2021 | 48.17 Million CNY | 60.41% |
| 2020 | 30.03 Million CNY | 1501686550.0% |
| 2019 | 2.00 CNY | 100.0% |
| 2018 | 1.00 CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 31.52 Million CNY | -100.0% |
| 2024 Q2 | 29.18 Million CNY | 0.0% |
| 2024 Q3 | 29.53 Million CNY | -100.0% |
| 2023 Q4 | 29.45 Million CNY | 1.05% |
| 2023 Q2 | 30.94 Million CNY | -14.81% |
| 2023 FY | 29.45 Million CNY | -68.42% |
| 2023 Q1 | 36.32 Million CNY | -61.06% |
| 2023 Q3 | 29.15 Million CNY | -5.8% |
| 2022 Q3 | 93.62 Million CNY | -2.63% |
| 2022 Q4 | 93.27 Million CNY | -0.37% |
| 2022 Q2 | 96.15 Million CNY | -2.72% |
| 2022 Q1 | 98.84 Million CNY | 105.18% |
| 2022 FY | 93.27 Million CNY | 93.62% |
| 2021 FY | 48.17 Million CNY | 60.41% |
| 2021 Q1 | 34.46 Million CNY | 14.77% |
| 2021 Q4 | 48.17 Million CNY | -49.88% |
| 2021 Q3 | 96.11 Million CNY | 135.51% |
| 2021 Q2 | 40.81 Million CNY | 18.41% |
| 2020 Q1 | 4.9 Million CNY | 1.69% |
| 2020 FY | 30.03 Million CNY | 1501686550.0% |
| 2020 Q3 | 4.26 Million CNY | 1.95% |
| 2020 Q2 | 4.18 Million CNY | -14.84% |
| 2020 Q4 | 30.03 Million CNY | 604.68% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 4.67 Million CNY | 0.0% |
| 2019 Q3 | 4.75 Million CNY | 1.61% |
| 2019 Q4 | 4.82 Million CNY | 1.59% |
| 2019 FY | 2.00 CNY | 100.0% |
| 2018 FY | 1.00 CNY | 0.0% |
| 2018 Q4 | 4.52 Million CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |